Dendritic cell dragnet
The inability of peripheral immune cells to penetrate the CNS protects the brain against inflammation but has thwarted efforts to stimulate immunity against brain cancer antigens. Now a team at Cedars-Sinai Medical Center has devised a way around this barrier using an immunomodulatory peptide called FMS-like tyrosine kinase 3 ligand.1
The finding is serendipitous for Celldex Therapeutics Inc., which in-licensed FMS-like tyrosine kinase 3 ligand (FLT3LG; FLT3L) from Amgen Inc. last year in hopes of using the molecule to mobilize myeloid progenitor cells.
The brain, the testes and parts of the eye are thought